Craig Hallum Trims Vivos Therapeutics (NASDAQ:VVOS) Target Price to $5.00

Vivos Therapeutics (NASDAQ:VVOSGet Rating) had its target price decreased by Craig Hallum to $5.00 in a research report issued to clients and investors on Tuesday, Stock Target Advisor reports. The firm presently has a “na” rating on the stock. Craig Hallum’s target price points to a potential upside of 262.32% from the company’s previous close.

Separately, Zacks Investment Research cut Vivos Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, April 9th.

NASDAQ VVOS traded up $0.03 during trading hours on Tuesday, hitting $1.38. 1 shares of the company were exchanged, compared to its average volume of 76,123. The stock has a 50-day moving average price of $2.13 and a 200 day moving average price of $2.54. Vivos Therapeutics has a 52 week low of $1.18 and a 52 week high of $7.09. The stock has a market cap of $31.75 million, a PE ratio of -1.41 and a beta of 0.84.

Large investors have recently made changes to their positions in the business. Renaissance Technologies LLC purchased a new position in shares of Vivos Therapeutics during the first quarter valued at approximately $29,000. Jane Street Group LLC purchased a new position in shares of Vivos Therapeutics during the third quarter valued at approximately $60,000. Blueshift Asset Management LLC purchased a new position in shares of Vivos Therapeutics during the third quarter valued at approximately $76,000. Cambridge Investment Research Advisors Inc. boosted its position in shares of Vivos Therapeutics by 60.0% during the fourth quarter. Cambridge Investment Research Advisors Inc. now owns 19,200 shares of the company’s stock valued at $43,000 after buying an additional 7,200 shares during the period. Finally, Schonfeld Strategic Advisors LLC purchased a new position in shares of Vivos Therapeutics during the third quarter valued at approximately $139,000. Institutional investors and hedge funds own 9.81% of the company’s stock.

About Vivos Therapeutics (Get Rating)

Vivos Therapeutics, Inc, a medical technology company, develops and commercializes treatment alternatives for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers the Vivos System, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring.

Featured Articles

Stock Target Advisor logo

Receive News & Ratings for Vivos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vivos Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.